The relationship of neuroendocrine carcinomas to anti-tumor therapies in TRAMP mice

Prostate

Volumn 69, Issue 16, 2009, Pages 1763-1773

  Tang, Yao ^a   Wang, Linbo ^a   Goloubeva, Olga ^a   Khan, Mohammad Afnan ^a   Lee, DongIk ^a   Hussain, Arif ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b BALTIMORE VA MEDICAL CENTER   (United States)

Author keywords

Neuroendocrine carcinoma; Prostate cancer; Tramp mice

Indexed keywords

ANDROGEN RECEPTOR; BREAST CANCER RESISTANCE PROTEIN; CALVASCULIN; CYCLINE; DOCETAXEL; GLYCOPROTEIN P; UVOMORULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CASTRATION; CONTROLLED STUDY; EXPERIMENTAL MODEL; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; MOUSE; NEUROENDOCRINE CARCINOMA; NEUROENDOCRINE TUMOR; NONHUMAN; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROTEIN EXPRESSION; TUMOR GROWTH; WESTERN BLOTTING;

ADENOCARCINOMA; ANDROGEN ANTAGONISTS; ANIMALS; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CARCINOMA, NEUROENDOCRINE; CELL PROLIFERATION; DRUG THERAPY, COMBINATION; INCIDENCE; MALE; MICE; MICE, TRANSGENIC; NEOPLASM PROTEINS; P-GLYCOPROTEIN; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS; TAXOIDS;

EID: 70350442988     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21026     Document Type: Article

References (51)

1. Shariff AH, Ather MH. Neuroendocrine differentiation in prostate cancer. Urology 2006;68:2-8.
2. Evangelou AI, Winter SF, Huss WJ, Bok RA, Greenberg NM. Steroid hormones, polypeptide growth factors, hormone refractory prostate cancer, and the neuroendocrine phenotype. J Cell Biochem 2004;91:671-683.
3. Nelson EC, Cambio AJ, Yang JC, Ok JH, Lara PN Jr, Evans CP. Clinical implications of neuroendocrine differentiation in prostate cancer. Prostate Cancer Prostatic Dis 2007;10:6-14. (Pubitemid 46358906)
4. Vashchenko N, Abrahamsson PA. Neuroendocrine differentiation in prostate cancer: Implications for new treatment modalities. Eur Urol 2005;47:147-155. (Pubitemid 40126970)
5. Stein ME, Bernstein Z, Abacioglu U, Sengoz M, Miller RC, Meirovitz A, Zouhair A, Freixa SV, Poortmans PH, Ash R, Kuten A. Small cell (neuroendocrine) carcinoma of the prostate: Etiology, diagnosis, prognosis, and therapeutic implications - A retrospective study of 30 patients from the rare cancer network. Am J Med Sci 2008;336:478-488.
6. Bonkhoff H, Remberger K. Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: A stem cell model. Prostate 1996;28:98-106. (Pubitemid 26066247)
7. Aprikian AG, Cordon-Cardo C, Fair WR, Reuter VE. Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma. Cancer 1993;71:3952-3965. (Pubitemid 23172976)
8. Bonkhoff H, Stein U, Remberger K. Multidirectional differentiation in the normal, hyperplastic, and neoplastic human prostate: Simultaneous demonstration of cell-specific epithelial markers. Hum Pathol 1994;25:42-46. (Pubitemid 24051823)
9. Civantos F. Difficulties in interpreting specimens after neo-adjuvant hormonal therapy and radiation with illustration of neuroendocrine differentiation. Mol Urol 2000;4:117-121; discussion 123. (Pubitemid 30808863)
10. Abrahamsson PA, di Sant'Agnese PA. Neuroendocrine cells in the human prostate gland. J Androl 1993;14:307-309.
11. Nakada SY, di Sant'Agnese PA, Moynes RA, Hiipakka RA, Liao S, Cockett AT, Abrahamsson PA. The androgen receptor status of neuroendocrine cells in human benign and malignant prostatic tissue. Cancer Res 1993;53:1967-1970. (Pubitemid 23145709)
12. Cox ME, Deeble PD, Lakhani S, Parsons SJ. Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: Implications for prostate cancer progression. Cancer Res 1999;59:3821-3830. (Pubitemid 29381892)
13. Pinski J, Wang Q, Quek ML, Cole A, Cooc J, Danenberg K, Danenberg PV. Genistein-induced neuroendocrine differentiation of prostate cancer cells. Prostate 2006;66:1136-1143. (Pubitemid 44175336)
14. Humez S, Monet M, Legrand G, Lepage G, Delcourt P, Prevarskaya N. Epidermal growth factor-induced neuroendocrine differentiation and apoptotic resistance of androgen-independent human prostate cancer cells. Endocr Relat Cancer 2006;13:181-195.
15. Lee SO, Chun JY, Nadiminty N, Lou W, Gao AC. Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression. Prostate 2007;67:764-773. (Pubitemid 46709445)
16. Burchardt T, Burchardt M, Chen MW, Cao Y, de la Taille A, Shabsigh A, Hayek O, Dorai T, Buttyan R. Transdifferentiation of prostate cancer cells to a neuroendocrine cell phenotype in vitro and in vivo. J Urol 1999;162:1800-1805. (Pubitemid 29474732)
17. Jongsma J, Oomen MH, Noordzij MA, Romijn JC, van Der Kwast TH, Schroder FH, van Steenbrugge GJ. Androgen-independent growth is induced by neuropeptides in human prostate cancer cell lines. Prostate 2000;42:34-44. (Pubitemid 30004873)
18. Jongsma J, Oomen MH, Noordzij MA, Van Weerden WM, Martens GJ, van der Kwast TH, Schroder FH, van Steenbrugge GJ. Different profiles of neuroendocrine cell differentiation evolve in the PC-310 human prostate cancer model during long-term androgen deprivation. Prostate 2002;50:203-215. (Pubitemid 34184659)
19. Huss WJ, Gregory CW, Smith GJ. Neuroendocrine cell differentiation in the CWR22 human prostate cancer xenograft: Association with tumor cell proliferation prior to recurrence. Prostate 2004;60:91-97.
20. Masumori N, Thomas TZ, Chaurand P, Case T, Paul M, Kasper S, Caprioli RM, Tsukamoto T, Shappell SB, Matusik RJ. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinomawith metastatic potential. Cancer Res 2001;61:2239-2249. (Pubitemid 32692054)
21. Kaplan-Lefko PJ, Chen TM, Ittmann MM, Barrios RJ, Ayala GE, Huss WJ, Maddison LA, Foster BA, Greenberg NM. Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate 2003;55:219-237. (Pubitemid 36532401)
22. Shappell SB, Thomas GV, Roberts RL, Herbert R, Ittmann MM, Rubin MA, Humphrey PA, Sundberg JP, Rozengurt N, Barrios R, Ward JM, Cardiff RD. Prostate pathology of genetically engineered mice: Definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res 2004;64:2270-2305.
23. Jensen SM, Gazdar AF, Cuttitta F, Russell EK, Linnoila RI. A comparison of synaptophysin, chromogranin, and L-dopa decarboxylase as markers for neuroendocrine differentiation in lung cancer cell lines. Cancer Res 1990;50:6068-6074. (Pubitemid 20331423)
24. Gingrich JR, Barrios RJ, Foster BA, Greenberg NM. Pathologic progression of autochthonous prostate cancer in the TRAMP model. Prostate Cancer Prostatic Dis 1999;2:70-75.
25. Tang Y, Wang L, Goloubeva O, Afnan Khan M, Zhang B, Hussain A. Divergent effects of castration on prostate cancer in TRAMPmice: Possible implications for therapy. Clin Cancer Res 2008;14:2936-2943.
26. Tang Y, Khan MA, Goloubeva O, Lee DI, Jelovac D, Brodie AM, Hussain A. Docetaxel followed by castration improves outcomes in LNCaP prostate cancer-bearing severe combined immuno-deficient mice. Clin Cancer Res 2006;12:169-174. (Pubitemid 43166191)
27. Masumori N, Tsuchiya K, Tu WH, Lee C, Kasper S, Tsukamoto T, Shappell SB, Matusik RJ. An allograft model of androgen independent prostatic neuroendocrine carcinoma derived from a large probasin promoter-T antigen transgenic mouse line. J Urol 2004;171:439-442. (Pubitemid 37549206)
28. Garabedian EM, Humphrey PA, Gordon JI. A transgenic mouse model of metastatic prostate cancer originating from neuro-endocrine cells. Proc Natl Acad Sci USA 1998;95:15382-15387. (Pubitemid 29018707)
29. Chiaverotti T, Couto SS, Donjacour A, Mao JH, Nagase H, Cardiff RD, Cunha GR, Balmain A. Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer. Am J Pathol 2008;172:236-246. (Pubitemid 351186384)
30. Erasmus CE, Verhagen WI, Wauters CA, van Lindert EJ. Brain metastasis from prostate small cell carcinoma: Not to be neglected. Can J Neurol Sci 2002;29:375-377.
31. Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, Aspinall JO, Cunha GR, Donjacour AA, Matusik RJ, Rosen JM. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 1995;92:3439-3443.
32. Wang W, Epstein JI. Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases. Am J Surg Pathol 2008;32:65-71.
33. Sakuma T, Yoshida T, Ohashi H, Nishimura K, Kawano K. Combined small-cell carcinoma/adenocarcinoma of prostate: Report of two cases. Hinyokika Kiyo 2007;53:489-492.
34. Wu C, Huang J. Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway is essential for neuroendocrine differentiation of prostate cancer. J Biol Chem 2007;282:3571-3583. (Pubitemid 47084471)
35. Yang JC, Ok JH, Busby JE, Borowsky AD, Kung HJ, Evans CP. Aberrant activation of androgen receptor in a new neuro-peptide- autocrine model of androgen-insensitive prostate cancer. Cancer Res 2009;69:151-160.
36. Mori R, Xiong S, Wang Q, Tarabolous C, Shimada H, Panteris E, Danenberg KD, Danenberg PV, Pinski JK. Gene profiling and pathway analysis of neuroendocrine transdifferentiated prostate cancer cells. Prostate 2009;69:12-23.
37. Tarabykina S, Griffiths TR, Tulchinsky E, Mellon JK, Bronstein IB, Kriajevska M. Metastasis-associated protein S100A4: Spot-light on its role in cell migration. Curr Cancer Drug Targets 2007;7:217-228. (Pubitemid 46699073)
38. Gao ZH, Tretiakova MS, Liu WH, Gong C, Farris PD, Hart J. Association of E-cadherin, matrix metalloproteinases, and tissue inhibitors of metalloproteinases with the progression and metastasis of hepatocellular carcinoma. Mod Pathol 2006;19: 533-540.
39. Kimura K, Endo Y, Yonemura Y, Heizmann CW, Schafer BW, Watanabe Y, Sasaki T. Clinical significance of S100A4 and E-cadherin-related adhesion molecules in non-small cell lung cancer. Int J Oncol 2000;16:1125-1131.
40. Qi RX, Xu XY. Inverse correlation of S100A4 and E-cad protein expression and their clinical significance in non-small cell lung cancer. Zhonghua Zhong Liu Za Zhi 2007;29:681-684.
41. Saleem M, Adhami VM, Ahmad N, Gupta S, Mukhtar H. Prognostic significance of metastasis-associated protein S100A4 (Mts1) in prostate cancer progression and chemoprevention regimens in an autochthonous mouse model. Clin Cancer Res 2005;11:147-153. (Pubitemid 40075789)
42. Saleem M, Kweon MH, Johnson JJ, Adhami VM, Elcheva I, Khan N, Bin Hafeez B, Bhat KM, Sarfaraz S, Reagan-Shaw S, Spiegelman VS, Setaluri V, Mukhtar H. S100A4 accelerates tumorigenesis and invasion of human prostate cancer through the transcriptional regulation of matrix metalloproteinase 9. Proc Natl Acad Sci USA 2006;103:14825-14830. (Pubitemid 44527813)
43. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat Rev Cancer 2002;2:48-58. (Pubitemid 37328807)
44. Brooks TA, Minderman H, O'Loughlin KL, Pera P, Ojima I, Baer MR, Bernacki RJ. Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Mol Cancer Ther 2003;2:1195-1205.
45. Bhangal G, Halford S, Wang J, Roylance R, Shah R, Waxman J. Expression of the multidrug resistance gene in human prostate cancer. Urol Oncol 2000;5:118-121. (Pubitemid 30182540)
46. Theyer G, Schirmbock M, Thalhammer T, Sherwood ER, Baumgartner G, Hamilton G. Role of the MDR-1-encoded multiple drug resistance phenotype in prostate cancer cell lines. J Urol 1993;150:1544-1547. (Pubitemid 24356225)
47. Doyle LA, Ross DD. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 2003;22: 7340-7358. (Pubitemid 37487163)
48. Papandreou CN, Daliani DD, Thall PF, Tu SM, Wang X, Reyes A, Troncoso P, Logothetis CJ. Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol 2002;20:3072-3080. (Pubitemid 34791096)
49. Tanaka M, Suzuki Y, Takaoka K, Suzuki N, Murakami S, Matsuzaki O, Shimazaki J. Progression of prostate cancer to neuroendocrine cell tumor. Int J Urol 2001;8:431-436; discussion 437. (Pubitemid 34225095)
50. Miyoshi Y, Uemura H, Kitami K, Satomi Y, Kubota Y, Hosaka M. Neuroendocrine differentiated small cell carcinoma presenting as recurrent prostate cancer after androgen deprivation therapy. BJU Int 2001;88:982-983. (Pubitemid 34099032)
51. Spieth ME, Lin YG, Nguyen TT. Diagnosing and treating small-cell carcinomas of prostatic origin. Clin Nucl Med 2002;27:11-17.